IRIS
BODINI, GIORGIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.377
NA - Nord America 2.039
AS - Asia 1.609
Continente sconosciuto - Info sul continente non disponibili 465
SA - Sud America 141
AF - Africa 31
OC - Oceania 4
Totale 15.666
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 11.057
US - Stati Uniti d'America 1.892
SG - Singapore 551
CN - Cina 407
VN - Vietnam 266
BD - Bangladesh 202
FR - Francia 115
BR - Brasile 75
CA - Canada 68
HK - Hong Kong 56
GB - Regno Unito 43
DE - Germania 41
FI - Finlandia 39
AR - Argentina 25
MX - Messico 25
JP - Giappone 23
ID - Indonesia 20
IN - India 18
NL - Olanda 17
EC - Ecuador 13
IQ - Iraq 13
CR - Costa Rica 11
JM - Giamaica 11
CO - Colombia 10
PH - Filippine 9
TR - Turchia 8
UA - Ucraina 8
CL - Cile 7
KE - Kenya 7
VE - Venezuela 7
ZA - Sudafrica 7
CH - Svizzera 6
RU - Federazione Russa 6
ES - Italia 5
GT - Guatemala 5
JO - Giordania 5
NI - Nicaragua 5
TT - Trinidad e Tobago 5
AU - Australia 4
IE - Irlanda 4
SA - Arabia Saudita 4
SE - Svezia 4
TN - Tunisia 4
UZ - Uzbekistan 4
AZ - Azerbaigian 3
DZ - Algeria 3
ET - Etiopia 3
HN - Honduras 3
LT - Lituania 3
MY - Malesia 3
NP - Nepal 3
PL - Polonia 3
PT - Portogallo 3
RS - Serbia 3
SV - El Salvador 3
XK - ???statistics.table.value.countryCode.XK??? 3
AT - Austria 2
BA - Bosnia-Erzegovina 2
BZ - Belize 2
CZ - Repubblica Ceca 2
IL - Israele 2
KR - Corea 2
LB - Libano 2
LC - Santa Lucia 2
LV - Lettonia 2
MA - Marocco 2
PE - Perù 2
PK - Pakistan 2
PR - Porto Rico 2
PY - Paraguay 2
RO - Romania 2
TH - Thailandia 2
BB - Barbados 1
BE - Belgio 1
BG - Bulgaria 1
BH - Bahrain 1
BY - Bielorussia 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EG - Egitto 1
GA - Gabon 1
GG - Guernsey 1
GP - Guadalupe 1
HR - Croazia 1
HU - Ungheria 1
IR - Iran 1
KH - Cambogia 1
KN - Saint Kitts e Nevis 1
LY - Libia 1
MD - Moldavia 1
ML - Mali 1
PA - Panama 1
SC - Seychelles 1
SI - Slovenia 1
TW - Taiwan 1
Totale 15.204
Salva come PNG Salva come JPEG
Città #
Genova 5.160
Genoa 3.883
Vado Ligure 928
Rapallo 771
San Jose 361
Ashburn 309
Singapore 226
Lauterbourg 103
Council Bluffs 99
Ho Chi Minh City 82
Beijing 77
New York 73
Hanoi 61
Santa Clara 59
Hong Kong 54
Boardman 46
Milan 43
Los Angeles 41
Phoenix 39
Helsinki 32
Frankfurt am Main 31
Orem 25
Rome 24
Chicago 21
Buffalo 19
Tokyo 19
Bordighera 17
Dallas 16
Mexico City 15
Bologna 13
Philadelphia 13
Toronto 13
Da Nang 12
Amsterdam 11
Columbus 11
Montreal 11
San José 11
São Paulo 11
Washington 10
Atlanta 9
Naples 9
Poplar 9
San Francisco 9
Tianjin 9
Charlotte 8
Houston 8
London 8
Haiphong 7
Lappeenranta 7
Mumbai 7
Queens 7
Seattle 7
The Bronx 7
Baghdad 6
Brasília 6
Brooklyn 6
Denver 6
Kingston 6
Memphis 6
Miami 6
Newark 6
Ninh Bình 6
Zurich 6
Amman 5
Cardiff 5
City of London 5
Cleveland 5
Des Moines 5
Dublin 5
Hamilton 5
Manchester 5
Minneapolis 5
Nairobi 5
Pittsburgh 5
Sacramento 5
Tampa 5
Bogotá 4
Boston 4
Brescia 4
Bắc Ninh 4
Cagliari 4
Can Tho 4
Charleston 4
Figino 4
Florence 4
Guangzhou 4
Guatemala City 4
Hải Dương 4
Iowa City 4
Jacksonville 4
Kyiv 4
Madison 4
Managua 4
Medford 4
Milwaukee 4
Modena 4
Norwalk 4
Orlando 4
Padua 4
Portland 4
Totale 13.082
Salva come PNG Salva come JPEG
Nome #
Proton pump inhibitors: use and misuse in the clinical setting 253
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications 230
Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. 225
Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index 221
Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease 217
Advancements in the use of manometry and impedance testing for esophageal functional disorders 212
A safety review of proton pump inhibitors to treat acid-related digestive diseases 205
Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. 204
A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD) 204
The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin 203
High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease 200
Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. 199
A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients 182
Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn’s disease. 174
Anti-TNF Antibodies For Prevention of Crohn's Disease Recurrence After Surgery: More Than An Hope. 174
Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases 174
Adalimumab trough levels and response to biological treatment in patients with Inflammatory Bowel Disease: a useful cut-off In clinical practice. 172
Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations 172
A Nodule, is a Nodule, is a Nodule: May Alpha-fetoprotein Make the Difference? 171
Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals 171
Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: the perfect storm 169
Impact of evidence-based medicine on treatment of patients with unresectable hepatocellular carcinoma 168
Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients 168
Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations 166
Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: Which implications in patients with Crohn's disease? 165
The appropriate use of proton-pump inhibitors 165
Active pharmacovigilance program in patients affected by psoriasis and inflammatory bowel diseases
 165
Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. 163
Letter: Biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease 163
Optimal management of constipation associated with irritable bowel syndrome. 162
Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease 162
A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease 158
The natural history of gastro-esophageal reflux disease: A comprehensive review 157
Epidemiology and natural history of gastroesophageal reflux disease 157
Comparison of the Safety and Efficacy of Ustekinumab and Vedolizumab in Patients with Crohn’s Disease: A Systematic Review and Meta-Analysis of Propensity Score Matched Cohort Studies 150
Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis 149
Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation 145
Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio 145
Tryciclic Antidepressants in Refractory GERD: Poorly Effective Drugs or Wrong Patients? 143
Course of oesophageal varices and performance of non-invasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease 143
Concerns related to COVID-19 pandemic among patients with Inflammatory Bowel Disease, and its influence on patients management 142
Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. 141
Autoimmune chronic atrophic gastritis: association between chronic proton pump inhibitors use and more severe atrophy and gastric intestinal metaplasia 140
Regression of Fibrosis After DAAs Treatment of Patients with HCV Cirrhosis: Transposability to Non-Decompensated Patients 139
Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. 138
Prevention of Crohn's disease recurrence after surgery: on the road to recovery. 138
Gastrointestinal involvement in systemic sclerosis 138
Translation and initial validation of the Medication Adherence Report Scale (MARS) in Italian patients with Crohn's Disease 138
The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders. 136
Association between esophageal motor disorders and pulmonary involvement in patients affected by systemic sclerosis: a retrospective study 134
Esophageal motility abnormalities in gastroesophageal reflux disease 133
Patient and physician views on the quality of care for inflammatory bowel disease after one-year follow-up: Results from SOLUTION-2, a prospective IG-IBD study 133
Applicability of Parameters for the Non-Invasive Diagnosis of Esophageal Varices Needing Treatment to Cured HCV Patients 133
Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value? 131
M01822 Diagnostic accuracy and Inter/Intra-observer Agreement between endoscopists with different expertise, before and after a short training, for the detection of gastric intestinal metaplasia by means of narrow band imaging with magnifying endoscopy 130
Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. 127
Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV 127
Esophageal testing: What we have so far 126
Reproducibility and transportability of the absence of incremental infectious adverse events in patients with higher anti-TNF drug levels 126
Institution of an interdisciplinary IBD centre is associated with improved healthcare utilisation 125
Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease. 125
Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered 125
A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study 123
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 121
Esophageal motor disorders across ages: A retrospective multicentric analysis 120
NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis 120
Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data 120
DEVELOPMENT AND VALIDATION OF A TEST TO MONITOR ENDOSCOPIC ACTIVITY IN PATIENTS WITH CROHN'S DISEASE BASED ON SERUM LEVELS OF PROTEINS 120
High-resolution manometry is superior to endoscopy and radiology in assessing and grading sliding hiatal hernia: A comparison with surgical in vivo evaluation 120
Impedance-detected symptom association and number of reflux episodes as pre-treatment parameters that predict outcomes of gastroesophageal reflux disease patients 115
Vonoprazan fumarate for the management of acid-related diseases 114
Granulocytes and monocytes apheresis induces upregulation of TGFβ1 in patients with active ulcerative colitis: A possible involvement of soluble HLA-I 114
Prevalence of Lactose Intolerance in Patients with Hashimoto Thyroiditis and Impact on LT4 Replacement Dose 113
Vegetal and animal food proteins have a different impact in the first postprandial hour of impedance-pH analysis in patients with heartburn 113
Treatment of early stage chronic hepatitis C virus infection 112
The Lyon Consensus: Does it differ from the previous ones? 111
Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment 111
Letter: Biological therapies are effective for prevention of post-operative Crohn's disease recurrence 108
Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 107
Elevated adherence to vaccination against SARS-CoV-2 among patients with Inflammatory Bowel Disease 107
Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand 105
Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? 105
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 101
Effect of hiatal hernia and esophagogastric junction morphology on esophageal motility: Evidence from high‐resolution manometry studies 100
Prospective evaluation on the prevalence of serrated adenoma during a two-year period in an italian endoscopy centre 100
Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques 99
Applying Lyon consensus criteria in the work‐up of patients with extra‐oesophageal symptoms – A multicentre retrospective study 97
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD 96
Food Intolerances, Food Allergies and IBS: Lights and Shadows 95
Intra- and interobserver Agreement between endoscopists and pathologists for detection of gastric intestinal metaplasia by means of narrow band imaging with magnifying endoscopy 95
Albumin-bilirubin score in non-malignant liver diseases should be properly validated 94
Prevention of postoperative recurrence of Crohn's disease by Adalimumab: a case series. 90
The crohn's disease exclusion diet in adults with mild-to-moderate crohn’s disease activity: A real-world open-label randomized controlled trial 89
Are Small Molecules Effective in Treating Inflammatory Pouch Disorders Following Ileal Pouch-Anal Anastomosis for Ulcerative Colitis? Here Is Where We Stand 89
Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility 89
Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease? 88
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator 86
Reduction of Fecal Calprotectin Levels Induced by a Short Course of Escherichia Coli Nissle is Associated with a Lower Likelihood of Disease Flares in Patients with Ulcerative Colitis in Clinical Remission 84
Clopidogrel-Induced Eosinophilic Colitis 84
From Dysbiosis to Hepatic Inflammation: A Narrative Review on the Diet-Microbiota-Liver Axis in Steatotic Liver Disease 84
Totale 13.990
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.551
article - articoli 55.551
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 111.102
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022927 0 0 53 83 35 114 38 238 79 117 51 119
2022/2023963 111 100 14 64 155 118 7 84 166 7 121 16
2023/2024804 28 80 12 106 72 144 64 29 31 35 73 130
2024/20252.427 106 145 116 132 302 269 177 433 104 92 252 299
2025/20264.990 511 211 449 435 538 355 633 219 398 513 306 422
2026/20271.008 473 240 295 0 0 0 0 0 0 0 0 0
Totale 15.666